Inhibition of LRP1 shedding reverses cartilage degradation in osteoarthritis

Published on Apr 1, 2018in Osteoarthritis and Cartilage4.793
路 DOI :10.1016/J.JOCA.2018.02.060
Kazuhiro Yamamoto17
Estimated H-index: 17
(University of Liverpool),
C. Scavenius1
Estimated H-index: 1
(AU: Aarhus University)
+ 7 AuthorsHideaki Nagase103
Estimated H-index: 103
(University of Oxford)
Source
Abstract
馃摉 Papers frequently viewed together
References0
Newest
Cited By2
Newest
#1Oliver McClurg (UEA: University of East Anglia)
#2Ryan Tinson (UEA: University of East Anglia)H-Index: 4
Last. Linda Troeberg (UEA: University of East Anglia)H-Index: 28
view all 3 authors...
Osteoarthritis is a common, degenerative joint disease with significant socio-economic impact worldwide. There are currently no disease-modifying drugs available to treat the disease, making this an important area of pharmaceutical research. In this review, we assessed approaches being explored to directly inhibit metalloproteinase-mediated cartilage degradation and to counteract cartilage damage by promoting growth factor-driven repair. Metalloproteinase-blocking antibodies are discussed, along...
2 CitationsSource
#1Qing Deng (SJTU: Shanghai Jiao Tong University)H-Index: 21
#2Xiaolan Yu (SJTU: Shanghai Jiao Tong University)H-Index: 3
Last. Yan Yu (SJTU: Shanghai Jiao Tong University)H-Index: 16
view all 8 authors...
Abstract Osteoarthritis (OA) is the most common disease of joint tissues; unfortunately, there are currently no curative therapies available for OA. Chondrocytes, the only cell type residing in cartilage, secrete many types of collagen (the mainly one is type II collagen) and aggrecan, which are the main components of the cartilage matrix. Chondrocyte apoptosis can lead to OA degenerative progression. We previously indicated that recombinant human midkine (rhMK), as a chondrocyte growth factor h...
4 CitationsSource